# Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine

> **NCT01820559** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 452 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Placebo
- **DRUG:** ESL 1200 mg
- **DRUG:** ESL 800 mg

## Key facts

- **NCT ID:** NCT01820559
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2013-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820559, "Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01820559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*